Genmab A/S Q2 Earnings Call Highlights

Genmab reported 1H 2026 revenue up 25% year over year and raised its full-year outlook, citing continued momentum from DARZALEX and EPKINLY. The company also scheduled additional late-stage trial readouts and announced two new Phase III petosemtamab studies in colorectal cancer, reinforcing its near-term pipeline. Overall, the combination of revenue growth, upgraded guidance, and expanded late-stage trials is a constructive update for investors.

Analysis

This is more important as a quality-of-earnings signal than as a one-quarter beat: GMAB is proving it can compound through royalty/partnered product exposure while still retaining pipeline optionality. That shifts the stock toward a hybrid profile—part cash-flow compounder, part biotech call option—which usually deserves a higher multiple than a pure pipeline name, especially when the growth is being funded by third-party commercial execution rather than internal burn.

The second-order winner is not just GMAB; it is any large-cap biotech platform that can show durable, non-dilutive revenue without sacrificing late-stage depth. By contrast, higher-beta biotech baskets should lag if investors rotate toward names with visible earnings and away from binary funding risk. The downside for GMAB is that the market may already be extrapolating too much from mature products, so the near-term upside from a guidance raise could be modest unless partner sell-through keeps compounding into the next two quarters.

Petosemtamab is the real long-duration catalyst, but new Phase III starts are not value creation until endpoint choice, comparator, and enrichment strategy are clear. In colorectal cancer, the bar is high and crowded, so the stock should trade more on readout quality than on study initiation. The contrarian read is that consensus may be underweighting the downside protection from royalties and overweighting the pipeline splash; if partner revenue stays intact, GMAB can rerate even if petosemtamab takes longer than expected.

Key Decisions for Investors

• Add GMAB on any post-news pullback for a 1-3 month hold; the setup is asymmetric because the raised outlook reduces near-term earnings risk while pipeline events preserve upside optionality. Falsifier: any sign of slowed DARZALEX/EPKINLY momentum in the next partner updates.
• Long GMAB / short XBI as a relative-value pair into the next 1-3 months. Thesis: investors will pay up for self-funded growth and de-risked revenue visibility while a broad biotech basket remains exposed to financing and readout risk.
• If trading options, use a 3-6 month call spread on GMAB rather than outright calls; this captures a modest rerating from guidance credibility while limiting premium paid if the market treats the raise as already priced.
• Treat upcoming Phase III disclosures as a watch item, not a buy trigger. The key missing data is whether petosemtamab is positioned for a biomarker-rich or broad CRC population; if design is less differentiated than expected, trim exposure into the event.
• Set an alert if the stock gives back the post-update move without any negative fundamental news; that would imply the market is fading the guidance upgrade and may offer a better entry than chasing strength.